Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Bortezomib, response and retreatment in 1st, 2nd, 3rd and 4th line of treatment in patients with multiple myeloma
Karolinska Inst Huddinge, Stockholm, Sweden..
Karolinska Inst, Stockholm, Sweden..
Janssen AB, Sollentuna, Sweden..
Karolinska Inst, Stockholm, Sweden..
Show others and affiliations
2012 (English)In: Haematologica, ISSN 0390-6078, E-ISSN 1592-8721, Vol. 97, p. 610-610Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
Ferrata Storti Foundation , 2012. Vol. 97, p. 610-610
National Category
Hematology
Identifiers
URN: urn:nbn:se:kth:diva-270716ISI: 000496830406054OAI: oai:DiVA.org:kth-270716DiVA, id: diva2:1414262
Note

QC 20200312

Available from: 2020-03-12 Created: 2020-03-12 Last updated: 2020-03-12Bibliographically approved

Open Access in DiVA

No full text in DiVA

Authority records BETA

Näsman, Per

Search in DiVA

By author/editor
Näsman, Per
By organisation
School of Architecture and the Built Environment (ABE)
In the same journal
Haematologica
Hematology

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 4 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf